Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib

Leukemia

Volumn 31, Issue 6, 2017, Pages 1333-1339

  Yu, J ^a   Chen, L ^a   Cui, B ^a   Wu, Christina ^a   Choi, M Y ^a   Chen, Y ^a   Zhang, L ^a   Rassenti, L Z ^a   Widhopf, G F ^a   Kipps, T J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CIRMTUZUMAB; IBRUTINIB; MONOCLONAL ANTIBODY; RAC1 PROTEIN; UNCLASSIFIED DRUG; WNT5A PROTEIN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAC1 PROTEIN, HUMAN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN; WNT5A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG SCREENING; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL PROLIFERATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, SCID; PYRAZOLES; PYRIMIDINES; RAC1 GTP-BINDING PROTEIN; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; TUMOR CELLS, CULTURED; WNT-5A PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85007579605     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.368     Document Type: Article

References (43)

1. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008; 264: 549-562.
2. Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013; 27: 173-206.
3. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2011; 2011: 96-103.
4. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313-4320.
5. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373: 2425-2437.
6. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
7. Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 1278-1279.
8. Komarova NL, Burger JA, Wodarz D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 2014; 111: 13906-13911.
9. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 2008; 105: 3047-3052.
10. Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proc Natl Acad Sci USA 2014; 111: 793-798.
11. Hofbauer SW, Krenn PW, Ganghammer S, Asslaber D, Pichler U, Oberascher K et al. Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. Blood 2014; 123: 2181-2188.
12. Kaucka M, Plevova K, Pavlova S, Janovska P, Mishra A, Verner J et al. The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration. Cancer Res 2013; 73: 1491-1501.
13. Yu J, Chen L, Cui B, Widhopf 2nd GF, Shen Z, Wu R et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest 2015; 126: 585-598.
14. Choi MY, Widhopf 2nd GF, Wu CC, Cui B, Lao F, Sadarangani A et al. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk 2015; 15(Suppl): S167-S169.
15. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075-13080.
16. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 2014; 123: 1229-1238.
17. Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K et al. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcgamma Receptor (FcgammaR) Function. J Biol Chem 2016; 291: 3043-3052.
18. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ et al. Specific Btk inhibition suppresses B cell-and myeloid cell-mediated arthritis. Nat Chem Biol 2011; 7: 41-50.
19. de Jong J, Sukbuntherng J, Skee D, Murphy J, O'Brien S, Byrd JC et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol 2015; 75: 907-916.
20. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
21. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629-635.
22. Gu Y, Filippi MD, Cancelas JA, Siefring JE, Williams EP, Jasti AC et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003; 302: 445-449.
23. Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 2014; 124: 1637-1644.
24. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci USA 2013; 110: 6127-6132.
25. Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 2014; 123: 3286-3295.
26. Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2014; 28: 649-657.
27. Nishita M, Itsukushima S, Nomachi A, Endo M, Wang Z, Inaba D et al. Ror2/Frizzled complex mediates Wnt5a-induced AP-1 activation by regulating Dishevelled polymerization. Mol Cell Biol 2010; 30: 3610-3619.
28. Naskar D, Maiti G, Chakraborty A, Roy A, Chattopadhyay D, Sen M. Wnt5a-Rac1-NF-kappaB homeostatic circuitry sustains innate immune functions in macro-phages. J Immunol 2014; 192: 4386-4397.
29. Zhu Y, Shen T, Liu J, Zheng J, Zhang Y, Xu R et al. Rab35 is required for Wnt5a/Dvl2-induced Rac1 activation and cell migration in MCF-7 breast cancer cells. Cell Signal 2013; 25: 1075-1085.
30. Velaithan R, Kang J, Hirpara JL, Loh T, Goh BC, Le Bras M et al. The small GTPase Rac1 is a novel binding partner of Bcl-2 and stabilizes its antiapoptotic activity. Blood 2011; 117: 6214-6226.
31. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
32. Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A et al. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood 2011; 118: 5235-5245.
33. Bosco EE, Ni W, Wang L, Guo F, Johnson JF, Zheng Y. Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis. Blood 2010; 115: 3320-3328.
34. Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013; 122: 3010-3019.
35. Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget 2016; 7: 4598-4610.
36. Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M et al. Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. Clin Cancer Res 2016; 22: 459-469.
37. O'Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein PC, Handel TM. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLOS One 2010; 5: e11716.
38. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med 2011; 364: 985-987.
39. Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2015; 100: 77-86.
40. Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salem D et al. Interactions between Ibrutinib and Anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res 2016; 22: 86-95.
41. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370: 2286-2294.
42. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol 2016; 9: 21.
43. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 323-332.